Mind Medicine Inc.’s $28.75 Million Bought Deal Prospectus Offering

Wildeboer Dellelce LLP acted for MindMed on the deal.

Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines and experiential therapies to address addiction and mental illness, completed a bought deal prospectus offering of 27,381,500 units for aggregate gross proceeds of $28,750,575. The offering was led by Canaccord Genuity Corp. as sole bookrunner and underwriter.

Wildeboer Dellelce LLP acted for MindMed in connection with the offering with a team comprised of Perry Dellelce (Picture), Peter Volk, Rebecca Cochrane and Katie Drury (corporate/securities) and Katy Pitch and Marija Tasevska (tax).

Involved fees earner: Rebecca Cochrane – Wildeboer Dellelce LLP; Perry Dellelce – Wildeboer Dellelce LLP; Katy Pitch – Wildeboer Dellelce LLP; Marija Tasevska – Wildeboer Dellelce LLP; Peter Volk – Wildeboer Dellelce LLP;

Law Firms: Wildeboer Dellelce LLP;

Clients: Mind Medicine Inc;

Print Friendly, PDF & Email

Author: Ambrogio Visconti